Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Thank you very much. I'm Simon Østergaard, President and CEO of the company, and I have Magnus Blix, our CFO, with me today. We appreciate you tuning in during this summer season to hear about our Q2 results and our performance halfway through 2024. We are pleased to share the outcomes with you. Let's just jump right into it. So, what do we call the quarter in brief? We achieved 11% growth in the quarter. Organically, that was 10%. This had hardly any impact on our results of $188 million in revenues. The EBITDA for the quarter was $60 million. That corresponds to an EBITDA margin of 32%. We exceeded our financial ambition by achieving over 30% in EBITDA. I'd say the highlights of the quarter were stability, albeit with some fluctuations. Top-level, we were very pleased with what we have seen in APAC across multiple countries. We see consistent performance out of the EMEA region. This quarter, we observed a temporary slowdown in the Americas. Regarding our strategic pillars, we have successfully completed internal preclinical studies for our bone marrow applications. We're now ready to proceed with external clinical validation throughout the autumn. This is an exciting phase for us. We have invested a significant amount of effort in interacting with new Sysmex colleagues across regional organizations to implement and adopt the Strategic Alliance Agreement that we signed with Sysmex in early February this year. All right. Let me delve deeper into the numbers. I know this format is busy, but it remains very informative. Here we have all the comparisons we need. We talked about the DIFF-Line and so on. On the very left-hand side, you see the new numbers we report today. In the middle column, we have the year-to-date figures for the year. We are now at $188 million for this quarter. Which brings us to $358 million, so far this half-year. This represents an organic growth of 16% year-to-date. For the gross margin, we are also reporting 66% this quarter. Um, that's a little bit low given the levers around product mix. We also have had increased material and product costs throughout the year. However, we have not seen a significant effect on the price increases that we implemented this year. So we should see them influence our gross margin when we get to Q3 operating expenses. Um, we have spent 75 million versus 73 million in the comparable quarter of last year. So I think we've been very successful in maintaining our cost base and sales despite some inflationary increases. That is due to some restructuring we did last autumn. Uh, the full impact of that on the admin, we are also pretty much in control, albeit increasing slightly. We are building a muscle for some of the regulatory requirements and therefore spending more. So here we are spending a bit more on consultants to be prepared and build support for our business in R&D. Um, it goes a little bit down. We are capitalizing more, from 14 million to 16 million this quarter. Uh, so that is really a sign of the maturity in our development programs. So that's good to see. Um, I mentioned the EBITDA of 60 million, which translates into a 32% margin. So, despite the somewhat lower gross margin, we still have a healthy EBITDA margin of 32%. Um, and cash flow wise, we had a cash flow, um, before adjustment for working capital of 54 million. So, given the overall, it's a good quarter, a solid quarter as we say. Um, however, given the growth we have, then we have some outstanding accounts receivable. And that brings our operating cash flow down to 40 million. And then if we deduct the investment activities, especially capitalized R&D of 16 million, but also other financial activities, That influences the cash flow. Then we have both dividend payouts of 54 million, And we also have the amortization and leasing of around 11 million. So that brings us down to a total cash flow of -44 million. So that's really, uh, a brief run through. Excuse me. Uh that's it. That's a brief run through of the personnel. Let's try and just give a bit of regional highlights. Mhm. So, as I said, on the top-line side, a little low or soft in the Americas. Um, and that is primarily on the large instrument site. So here we did have some operational matters that actually impacted the installation pace. There has been a bit of a drag in the Americas this quarter. We don't believe it's systemic with regards to market demand. We have seen continued interest and double-digit growth in our small instruments, and that is an interest that spans across the entire Americas. This is still super promising and really emphasizes the opportunities we have to serve the networks in that part of the world, but also in South America. In fact, looking at India, sales increased to $83 million versus $76 million, marking another quarter of growth in the Americas. This is promising, showing 10% growth this quarter and 15% year over year. It's really good to see how we have started to work and establish joint action plans across multiple markets. We are getting a better understanding and supporting how we leverage our system and materials to really convert and adopt digital cell morphology across this region. We also received very positive feedback from our participation at the ESL show in France, in May.<>br /> > That was rewarding and also very motivating for us, giving first-hand customer feedback on some of the innovation projects we're working on in APAC. In fact, it was pretty much a record high. We saw a 198% growth, achieving $37 million versus $13 million. That's obviously a very high growth number. Again, it fluctuates quite a bit in that region, because we are very dependent on when we ship to that part of the world where we sometimes ship quite a lot of instruments, and sometimes there are hardly any for certain jurisdictions. What I'm very pleased about with this number is that it's spread across multiple jurisdictions. We're seeing a comeback on track in Japan. We’ve been suffering. We had a year with inventory issues in Japan. But we are out of the woods now. There's a healthy demand from Japan and from China again. We are actually also starting to see some really interesting developments in Australia. This is not just a high revenue number, but it's also a very positive outlook. Also, given the more collaborative approach that we are starting to implement with our distribution partners and distribution across that region, if we analyze the numbers per product group as shown here. Again, there was 16% growth on the instrument side altogether, totaling $107 million. This is a significant increase from the comparable period. We take the six-month period to be $199 million versus $158 million. That's a healthy number. Again, I see instrument sales in APAC. As I just mentioned, but I would also highlight this line, which includes our smear box, the stain box, and the DC one that are gaining a lot of traction and attention in Canada and Latin America. So here we are, really working on getting ready for that and having the registrations there. The pre-marketing and the conversations with the labs are ongoing. And that seems to really resonate. The value proposition of this DIFF-Line really resonates with the labs in those markets. On the reagent side, 1%. It's a bit soft, at face value. So it's definitely lower than when we take it quarter by quarter. It is lower than usual, I think. Here, actually, our full year or year to date, Sorry, our year to date number of 10%, really demonstrates that we had a strong Q1. So there's a little bit of facing here. But, I also want to say that our compare here is actually relatively high. When we talk about growth, we also had some production issues last year, which meant that we shipped quite a bit in Q2. So the comparison is also a little bit tough against us in this very quarter. And still, momentum across the business. We are really pushing out the reagents, especially hematology reagents, where we see growth across India. We are starting to also get the benefits of the capacity expansion that we implemented with the new factory completed at the end of last calendar year. On the software side, we increased a few million to 44 million versus the compare. Here I think the highlight is definitely that we are starting to see not only the EMEA growth in general, but the software sales are picking up. It's really good. It is a sign of them also adopting our remote review. And that is very healthy. I think that is probably the relevant comment for that. To summarize, the key takeaways point to what we define as a solid quarter. But of course, in this business, as it's not a consumable business, We do have some soft aspects here that we actually don't believe are systemic. But we definitely saw the appetite and the orders coming from APAC as a highlight and as a positive sign. We saw a bit of a slowdown in the installation pace in the Americas that we believe will be recovered. Again, very good to see the software in the medium. Good progress. Today, I chose to report a little on the bone marrow as just to follow through, given our previous communication that we expect to commercialize our bone marrow molecule during 2025, which is the plan we are pursuing. And then again, the collaborative efforts with Sysmex in particular are really progressing. And I really highly appreciate the way we've started to work at multiple levels within the organizations. So that also gives a very energizing impact within our organization here at Celebration. With that, I will open for questions.
If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Ulrich Ratner from Carnegie. Please go ahead.
Hi. Thanks for taking my questions. A few, perhaps we can start off with America and the things you are seeing as temporary or declining, and you talk about operational matters impacting installation. If you can allude a little bit more to that, and if there is any chance of that sort of picking up in Q3, that is lagging or what these operational matters include, that would be my first question, please.
No thanks. Alright, I totally get the question. And this is where I should probably not overstep my situation in elaborating on things that are happening with our partners. But it is operational matters where we probably expected a little bit more on the large hand side on the large instrument side in terms of orders and given some focus on actually getting all hands on deck and installing what they had, then they didn't expand the order pattern in that. So the actual operational matters are not related to activities within television, but it's really on the partnering side. So it is a little bit tricky for me to elaborate on that and just guess here. So I will leave it for our partners to be open on whatever challenges that may be, but we get the full impression that it is a temporary piece. And I think we also signaled in our report that we believe it's over and out by now. But we have been impacted. So I'm sorry I can't give you the fully fledged internal insights on this one.
Fair enough. If we're to switch markets to APAC, it looks like a blowout quarter. Instruments grew four and a half times year over year. And it would be a two-part question. You talk about broad-based growth out of Japan, Australia, and even China. The first question would be, are you seeing any sort of material impacts on the competition side from Mindray? And secondly, as we have seen historically, is there any risk of inventory being built up here in Q2? And should we expect this trend to potentially not continue into the second half? Or how should we interpret this sort of very strong sales number.
No, I think it's definitely positive. If we start with Japan, it's very positive since we've been impacted. We know that there have been inventory levels. They've now been consumed, which demonstrates the demand. And we also know that there are some relatively big labs in Japan who are really digitalizing and replacing lines. So, I think Japan is really true consumption. I wouldn't look at that as a potential inventory matter for China. I think it's extremely healthy that we, quarter after quarter, have seen shipments going to China. That has really lifted our APAC numbers over the last few quarters. Here, we also see it as a sign of demand. Of course, the market is also dominated on the sell side by Mindray. There's definitely placements out there. The tricky thing is from our chair and even with our partner mix, it's very difficult to look at the layer of distributors that are actually meeting the hospitals, because that's not the manufacturing vendors. Who's doing that? So, there can be some inventory, but since we've seen this supply of instruments consistently, I truly believe that we are doing a pretty good job out there together with the specialist mix for APAC. Sorry for Australia. I think that's a promising jurisdiction. There is really an appetite to digitalize labs, and it resembles the Canadian market where we know that our value proposition is attractive. And that's actually what we start to see. So, we find the Australian and also small instruments going to Australia as super interesting and really supporting our ecosystem's adoption. So, that would be the highlight from APAC. Alright. Great.
And switching to Mia. First would be if you're experiencing, as we have seen for a lot of other companies in the diagnostic space and in general CapEx space, limitations around markets resetting post-pandemic and sort of budget restrictions, as well as noting software revenues increasing in EMEA. You touched upon this, and would you call software adoption more tilted towards certain countries or a general trend in Europe to go more in the direction where the U.S. has been developing for the last few years.
So that's a good point. I think also, that it is probably also a function of the fact that we are starting to see DC ones. Once we've seen a consistent flow of DC ones. But there are the fraction of connected labs across Europe is a little bit less than in the US. However, there are still a significant amount of labs where they really benefit from remote review. So I think that is part of the explanation that they really tie together the DC one with the large instruments. I totally hear you in terms of that. Could be some reservation on the budgeting side for health care. If you look at a high level, we must acknowledge that pressure is present, and when we engage with the community, that is probably the situation. However, we have been seeing modest growth for a couple of quarters now, which is encouraging on our side. So if we focus on our operational level, we're actually seeing traction, which is a healthy development. We are also trying to interpret macro events and the time delay between budgeting challenges in the healthcare system. How does that translate into the timing of tenders and so forth for our business? But right now, in our scope, it's actually a really healthy confirmation of our value proposition. Great.
And the last question on my end would be regarding the gross margin. You've stated quite clearly that you expect the gross margins to be favorably impacted by the recent price increases, heading into the second half of the year. Generally, and if I'm not mistaken, the effects of the price increases usually become apparent in Q2. Is there any reason for a delay in the impact of price changes on the gross margin? Secondly, you have increased your production capacity for highly reactive reagents. I'm assuming it's related to the build-out facility in Bordeaux. Is there something that can be done in terms of improving the gross margin of the reagents as well, or is it something that is impacted by these recent investments?
Those are good questions. You demonstrate that you've been following us for quite some years. Because you are right that typically, or historically, we've seen an impact in Q2. And there is a change. So, with a significant contract, we have changed the timing of implementing the price adjustments from Q1 to Q2. And that is really the main driver for the situation here. And when we talk about pricing, all orders that had been placed before Q2 were at old prices. And what we report here is that a significant part of the orders were placed before. So that is the reason why we have this phase change just this year. And I don't believe there's a material impact coming from the new factory that would translate into the gross margin on the retail side. I think that would be confirmed by my colleague here, and he's confirming my statement.
Improvements might come later on. But it takes a longer time before you see that reflected in the gross margin. So those projects are ongoing, but it's a gradual improvement that we will be seeing in the coming quarters and years, I would say.
Just a clarification, but do you expect that there is an opportunity to increase gross margins for reagents in the coming years? If we were to look at the medium term?
Yes, there is some opportunity to do gradual changes.
Definitely. But the question around the current state, that's not specifically on the radar. That was my point. Yeah.
Yes, yes.
Absolutely. But definitely, we're working on that agenda as well.
Great.
Um, that was all the questions on my end, and I'll get back in the queue. Thank you very much.
Yeah, thanks.
The next question comes from Ludwig Lundgren from Nordica. Please go ahead.
Yes. Hi, Simon and Magnus. So, maybe continuing a bit on this last question from Aldrich. So, maybe if you can elaborate a bit on the magnitude of these price hikes and what price effect we could expect here in Q3, then when the full effect is seen on sales and gross margin.
Yeah, I think it's, so it isn't. So there's both a component around product mix. And then there's the pricing I would highlight. So it's a mixed balance. I'd probably steer out of this specific quantitative component in your question because I think that would be borderline confidential. As to how much we get from the price increases, but we are very certain that we will see a difference. And then there's also a little bit of fluctuation, but quarter by quarter also on the depreciation of things. And so that's another thing. And then the final thing I would comment upon is, of course, the piece which sits in the gross margin as well. And then you can comment whether I actually went around the circle here, whether I got everything influencing the gross margin.
Now, I think you got it perfectly. And I think a valid comment would also be that the effect this year compared to last year is less visible. We had stronger price increases related to compensation for cost pricing increases last year.
That's a very good point. Yeah. So last year we, I shouldn't say aggressive, but we were really compensating also from higher material cost prices, which have, by the end of the day, sort of everything else being equal, they have been less, which has also translated us into being less, let's say pushy on increasing our prices because we also want to remain competitive.
Got it. So then I understand it, the gross margin is then more related to product mix than from actually the price or like cost of goods sold increases in the recent two quarters.
It is definitely influenced by the product mix. Definitely. But I'd say it's not negligible — the price rise. We do expect a lift from that.
Okay, great.
Um, and then also in the report, you mentioned the collaboration efforts with Sysmex during the quarter. And I've seen Sysmex market deploying quite actively in multiple markets. Could you maybe elaborate a bit on this, and maybe other efforts that I haven't seen.
Yes, a lot of it has been internal and thus not exposed. We expect to be more exposed as we do more things together, and this will become more visible to the market. Um, but we have really progressed on the sales side, and the way we work with the organization, we're getting more exposed at the country level, not just at the regional level. You could almost say at the headquarters level. Um, but also at the country level so that we can work specifically on training plans and really push the digital engagement already. We're looking at how to deploy our systems so that we can train both our colleagues in sales and the entire Sysmex organization. But it's, of course, also for the end users. So, how do we leverage our system, our e-learning platforms, and all our materials? So that is an exciting initiative that is ongoing. Then we have exposure at conferences. Um, in a week we will be at the ADM in Chicago. Um, so that is always a very rewarding show, both for talking with partners and customers. And here, we are also very collaborative in the way we present and work together at the booth, etc.
All right. Thanks.
Uh, and maybe continuing a bit on this. Uh, so you say that the small laboratory instruments continue to show double-digit growth in Q2. Uh, could you elaborate a bit on, like, the sales share of large versus small instruments?
Sorry. Uh.
So, sales.
Yeah, this share, this share of sales for small versus large because I'm guessing now with large being down quite a bit. Year over year, and small still growing, it's becoming more of a significant share of sales.
Yes, it is actually. I think we haven't reported the split between small and large instruments. Um, so I'll probably defer on that. And that's really just for competitive reasons. We are continuing to see this double-digit growth of the small instruments. It's fueled, in particular, by what we see in the Americas. What is particularly encouraging is that we actually expect an uptake in Canada. So when I said Americas just before, I alluded to North America, the U.S., but also to Canada, and now the appetite for a decent amount of our DC products going to especially Brazil is really taking off. And then we know there's untapped potential also across EMEA. This is for the small app segment, primarily due to the fear of blood. As I alluded to, remember the bone marrow specialty agenda that we are driving development-wise, which will be hosted by the DC one, and the prime market for that will be the large lab segment. So eventually, we really believe that there will be an uptake of DC1 also as we get into 2025 with bone marrow applications and by 2026, we will see an uptake of DC1 also in the large lab segment. So, it is proven to be a super stable and very good unit because it doesn’t take up a lot of bench space. It really endorses and enables us to build this ecosystem across labs.
This webcast event featured a detailed presentation of the financial and operational performance of a healthcare-focused company for the first half of the year 2024.
Great. Uh, so on the bone marrow, which you just mentioned, I saw that scope you got there received FDA clearance, I think, for their application. And maybe could you comment a bit on how your product compares to theirs? And do you see that you have better synergies since you have a larger installed base of your instruments? Are they able to sell their applications to your instruments, or do you have an advantage there?
First of all, I think on behalf of the patients, I congratulate Scorpio for pushing the industry boundaries and securing the registration for bone marrow. I actually think it's good. Um, then I think it's, um, it's tricky for me to comment on our product until we actually have the registration, because that's what we are chasing. Having said that, I, not just to be biased, but I do believe we have a better workflow solution that we will come out with, that will cater to a broader perspective of slides going into the workflow. Additionally, with a remote review, because of the installed base and the setup that we currently have. I think it's still good that the Novo application for bone marrow was done by Scorpio. So, once again, I congratulate them on that. That pushes the boundaries for how you can digitalize. But again, I remain unclear about the adoption of their system, which is unknown to me.
All right.
That's all the questions for me. Um, thanks for taking my questions.
My pleasure.
As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.
Yeah, thank you very much. And again, thanks to all for taking the time to listen in on our Q1 and half-year results. Just a few reflections before we can all go on a bit of a very tiny vacation. Then I just want to emphasize that, of course, we are proud of what the team has accomplished with our partners. It's been a solid quarter in this industry, and with our business, there will always be a little bit of fluctuation that we are working on across quarters and regions. Uh, this is also what we see. Having said that, I'm very proud that we've started the year, the first half with very robust quarters giving us an organic growth of 16%. And I also want to emphasize that the focus we've had this quarter, and not the least, the last quarter, we closed the 15-year Strategic Alliance Agreement with Sysmex, and that has really endorsed and demonstrated a mutual, relentless desire to connect and collaborate, which we've seen here in Q2. So a lot of traveling, a lot of meetings, a lot of interactions. A sincere thanks to all our involved parties and finally our investments into innovation. It remains focused and super dedicated. We have a number of progressing projects. Uh, so that is exciting. We talked a little bit about the bone marrow applications as an example, but we will certainly share more as we pave our way into the future. So with that, I just want to thank you all for dialing in and I wish you a great summer. Looking forward to communicating with you guys. You know, awesome. Thanks.



















